Psychopharmacology bulletin
June 5, 2026
Michael E Thase, Brian Brennan, Rachael Macisaac et al.
In patients with treatment-resistant depression, a single-day individualized dosing regimen of inhaled GH001 (synthetic mebufotenin) produced rapid and large improvements in depressive symptoms compared with placebo in a Phase 2b trial, with 57.5% achieving remission at Day 8 versus 0% on placebo. A post hoc analysis of 40 patients who received GH001 found no meaningful correlation between the number of prior lifetime antidepressant treatment failures and improvement on the Montgomery-Åsberg Depression Rating Scale at Day 8 or among 6-month open-label extension completers. Remission rates at Day 8 were similar across subgroups with 2, 3, 4, or 5 or more prior failures (range 53.9%-63.6%) and were maintained at Month 6 (range 61.5%-85.7%). The efficacy of GH001 appears largely independent of how many prior antidepressant treatments a patient has tried.
Frontiers in pharmacology
January 1, 2026
Joseph Geraci, Erik Viirre, Bessi Qorri et al.
Classic psychedelics like LSD, psilocybin, and DMT affect perception and brain plasticity mainly by activating the 5-HT2A receptor and triggering calcium-dependent signaling. A speculative but testable hypothesis suggests these biochemical cascades might connect with quantum processes in the brain, specifically through nuclear spin dynamics in phosphate-based 'Posner molecules' (Ca9(PO4)6). Intense 5-HT2A-driven neural activity and calcium flux during psychedelic use could allow phosphorus nuclear spins in these molecules to become entangled and shielded from decoherence, later influencing neuronal signaling when the clusters release calcium. This framework, building on Fisher's quantum cognition model, proposes testable predictions and outlines short-, medium-, and long-term experiments to confirm or refute quantum involvement, which could transform understanding of mind-brain relationships and psychiatric treatment.
Journal of Psychopharmacology
July 14, 2019
Livia Ng, Luca Pani, Anaïs Soula et al.
Claims about the positive effects of microdosing psychedelics on mood and cognition have entered public discussion, but scientific studies are scarce and no consensus on what microdosing means exists. This critique identifies questions future research must answer and offers guidelines, focusing on psilocybin due to its potential clinical approval and short-lasting effects. While anecdotal reports emphasize benefits, the paper concludes that future studies should also investigate potential risks of repeated low-dose administrations. Preclinical and clinical research examining biological measures like heart rate and receptor turnover, as well as cognitive parameters such as memory and attention, is needed to uncover possible negative consequences.